View Older Stories View More Recent Stories

Feb 23, 2024 07:30AM TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2023 Financial Results and Business Update
Feb 20, 2024 07:30AM TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
Jan 10, 2024 07:01AM TG Therapeutics (TGTX) Reports Prelim Q4 Results, 2024 Anticipated Milestones
Jan 10, 2024 07:00AM TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2023 Net Revenue and 2024 Anticipated Milestones
Jan 9, 2024 07:00AM TG Therapeutics Announces Global License Agreement with Precision BioSciences for the Development and Commercialization of Precision’s Allogeneic CD19 CAR T Cell Therapy Program for the Treatment of
Jan 5, 2024 07:30AM TG Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
Nov 27, 2023 07:30AM TG Therapeutics to Participate in the 6th Annual Evercore ISI HealthCONx Conference
Nov 3, 2023 07:30AM TG Therapeutics to Participate in the 5th Annual Guggenheim Inflammation, Neurology & Immunology (INI) Conference
Nov 1, 2023 07:30AM TG Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results
Oct 30, 2023 07:30AM TG Therapeutics to Host Conference Call on Third Quarter 2023 Financial Results and Business Update
Oct 12, 2023 11:00AM TG Therapeutics Announces Presentation of Data for BRIUMVI at the 2023 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting
Oct 11, 2023 10:30AM TG Therapeutics Announces Presentation of Data for BRIUMVI at the 2023 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting
Oct 2, 2023 07:30AM TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI at the 2023 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting
Sep 22, 2023 07:30AM TG Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference
Sep 7, 2023 07:30AM TG Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
Aug 1, 2023 07:20AM TG Therapeutics (TGTX) and Neuraxpharm Announce Ex-US Commercialization Agreement for BRIUMVI
Aug 1, 2023 07:15AM TG Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results
Aug 1, 2023 07:00AM TG Therapeutics and Neuraxpharm Announce Ex-US Commercialization Agreement for BRIUMVI® (ublituximab-xiiy)
Jul 31, 2023 08:30AM TG Therapeutics to Host Conference Call on Second Quarter 2023 Financial Results and Business Update
Jun 5, 2023 07:30AM TG Therapeutics to Participate in the 2023 Jefferies Healthcare Conference
Jun 2, 2023 09:15AM TG Therapeutics Announces Presentation of Data from the ULTIMATE I & II Phase 3 Trials of BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the 2023 Consortium of Multiple Sclerosis Centers An
Jun 1, 2023 09:15AM TG Therapeutics (TGTX) Announces European Commission Approval for BRIUMVI for the Treatment of Relapsing Forms of Multiple Sclerosis in Adults
Jun 1, 2023 09:15AM TG Therapeutics Announces European Commission Approval for BRIUMVI® (ublituximab-xiiy) for the Treatment of Relapsing Forms of Multiple Sclerosis in Adults
May 31, 2023 07:40AM TG Therapeutics (TGTX) Announces Data from ULTIMATE I & II Phase 3 Trials of BRIUMVI in Multiple Sclerosis to be Presented at CMSC
May 31, 2023 07:30AM TG Therapeutics Announces Data from the ULTIMATE I & II Phase 3 Trials of BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis to be Presented at the 2023 Consortium of Multiple Sclerosis Centers An
May 4, 2023 07:30AM TG Therapeutics to Participate in the Bank of America Securities 2023 Health Care Conference
May 1, 2023 07:30AM TG Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results
Apr 28, 2023 04:30PM TG Therapeutics to Host Conference Call on First Quarter 2023 Financial Results and Business Update
Apr 27, 2023 07:30AM TG Therapeutics (TGTX) Announces Issuance of Permanent J-Code for BRIUMVI
Apr 27, 2023 07:30AM TG Therapeutics Announces Issuance of Permanent J-Code for BRIUMVI® (ublituximab-xiiy) from Centers for Medicare and Medicaid Services
Apr 25, 2023 08:00AM TG Therapeutics Announces Presentation of Data from the ULTIMATE I & II Phase 3 Trials of BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 75th Annual Meetin
Mar 31, 2023 07:31AM TG Therapeutics (TGTX) Announces Positive CHMP Opinion for BRIUMVI for the Treatment of Relapsing Forms of Multiple Sclerosis in Adults
Mar 31, 2023 07:30AM TG Therapeutics Announces Positive CHMP Opinion for BRIUMVI™ (ublituximab-xiiy) for the Treatment of Relapsing Forms of Multiple Sclerosis in Adults
Mar 3, 2023 08:31AM TG Therapeutics (TGTX) Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of BRIUMVI
Mar 3, 2023 08:30AM TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of BRIUMVI™ (ublituximab-xiiy) in Multiple Sclerosis to be Presented at the American Academy of Neurology 75t
Feb 28, 2023 07:30AM TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2022 Financial Results
Feb 24, 2023 07:30AM TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2022 Financial Results and Business Update
Feb 24, 2023 07:01AM TG Therapeutics (TGTX) Announces Presentation of Data from the ULTIMATE I & II Phase 3 Trials of BRIUMVI
Feb 24, 2023 07:00AM TG Therapeutics Announces Presentation of Data from the ULTIMATE I & II Phase 3 Trials of BRIUMVI™ (ublituximab-xiiy) in Multiple Sclerosis at the Americas Committee for Treatment and Research i
Feb 14, 2023 07:30AM TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of BRIUMVI™ (ublituximab) in Multiple Sclerosis to be Presented at the Americas Committee for Treatment and R
Jan 26, 2023 07:08AM TG Therapeutics (TGTX) Announces Commercial Launch of BRIUMVI
Jan 26, 2023 07:00AM TG Therapeutics Announces Commercial Launch of BRIUMVI™ (ublituximab-xiiy) for the Treatment of Adult Patients with Relapsing Forms of Multiple Sclerosis
Jan 6, 2023 07:30AM TG Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
Dec 28, 2022 01:49PM TG Therapeutics (TGTX) Confirms FDA Approval of BRIUMVI (ublituximab-xiiy)
Dec 28, 2022 01:48PM TG Therapeutics Announces FDA Approval of BRIUMVI™ (ublituximab-xiiy)
Nov 10, 2022 07:30AM TG Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial Results
Nov 8, 2022 07:30AM TG Therapeutics to Host Conference Call on Third Quarter 2022 Financial Results and Business Update
Oct 26, 2022 07:30AM TG Therapeutics Announces Presentation of Exploratory Analyses from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis Presented at the 2022 European Committee for Treatment a
Oct 13, 2022 07:30AM TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at the 2022 European Committee for Treatment and Research
Sep 9, 2022 07:30AM TG Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
View More Recent Stories View Older Stories